arrow_back Trending Legislation
Share share

Prohibiting Pay-for-Delay Drug Deals: Lowering Medication Costs

This act aims to lower drug prices by prohibiting brand-name drug companies from paying generic companies to delay the market entry of cheaper alternatives. This means citizens can expect faster access to more affordable medications, positively impacting their personal finances and healthcare access.
Key points
Bans payments for delaying the market entry of generic and biosimilar drugs, aiming to boost competition.
Introduces financial penalties for companies violating these rules, discouraging unfair practices.
Requires certification of agreements between companies to ensure transparency and prevent hidden deals.
article Official text account_balance Process page notifications_active Track this Bill
gavel
Status:
Expired
Record your position for audit.
Why does your vote on bills matter?
It creates raw, undeniable proof. Civic Will provides the permanent data to verify the Government's loyalty towards its citizens (explained here). Start recording it now.
Additional Information
Preserve Access to Affordable Generics and Biosimilars Act
Print number: S 1428
Sponsor: Sen. Klobuchar, Amy [D-MN]
Process start date: 2021-04-28
System Note: Lustra is free, publicly auditable civic infrastructure, with full source code available on GitHub. You are reading sterilized legislative data, processed by our radical neutrality engine to strip political spin and retain factual mechanics. We process only official government data. Original documents remain the authoritative source, always verify them if you can.
Summarized by: gemini-2.5-flash-preview-05-20
Source data: api.congress.gov
AI work logs for this document launch
Summary & Status

Key Questions about Prohibiting Pay-for-Delay Drug Deals: Lowering Medication Costs

A structured overview of the legislative process, official sources, status and civic context.

What is the official ID of this bill?

The official print number for this legislation is S 1428.

Which chamber initiated this legislation?

This legislation was initiated in the Senate.

When did the legislative process begin?

The process officially started on 2021-04-28.

What are the main provisions?

Key points include:

  • Bans payments for delaying the market entry of generic and biosimilar drugs, aiming to boost competition.
  • Introduces financial penalties for companies violating these rules, discouraging unfair practices.
  • Requires certification of agreements between companies to ensure transparency and prevent hidden deals.

What is the specific legal status?

The current status is Expired.

Where can I read the full text of this legislation?

The full official text is available at: View full text

Who is the primary sponsor?

The primary sponsor is Sen. Klobuchar, Amy [D-MN].

What is the latest detailed status?

The latest detailed status is: Placed on Senate Legislative Calendar under General Orders. Calendar No. 180.

Is this summary verified?

Yes. This content was analyzed by AI and verified by the Lustra Judge System on 2025-12-29.

Analysis and Potential Impact of S 1428

We don't know, that is up to you to decide. Summarizing raw data with AI is fundamentally different from predicting socio-economic outcomes. As of 2026, we believe impact assessment strictly requires a human in the loop to verify and judge. Review our public AI processing logs for full transparency, and use Lustra to track active legislation for instant status push notifications.

CATEGORIES

Health Courts and Law Economy